The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved MSD’s anti-programmed death receptor-1 (PD-1) therapy ...

This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

新泽西州拉威市 - 默沙东集团（在美国和加拿大以外地区称为MSD）的抗PD-1疗法KEYTRUDA（pembrolizumab）获得日本厚生劳动省（MHLW）批准，用于特定肺癌和尿路上皮癌的新适应症。 获批的适应症包括KEYTRUDA联合化疗作为新辅助治疗，随后KEYTRUDA单药作为辅助治疗，用于非小细胞肺癌（NSCLC）患者。这一批准基于KEYNOTE-671三期临床试验结果，该试验显示与化疗 ...